FDA Approves Outlook Therapeutics' Lytenava as First Ophthalmic Bevacizumab for Wet AMD
On July 24, 2026, the U.S. Food and Drug Administration (FDA) approved Outlook Therapeutics' Lytenava (bevacizumab-vikg) for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). The landmark approval establishes Lytenava as the first and only FDA-approved ophthalmic formulation of bevacizumab in the United States, bringing a regulated, purpose-built version of a molecule that has been used off-label in retinal clinics for more than two decades.
A Major Structural Shift for the $8.5 Billion Retina Market
Bevacizumab (originally marketed as Avastin for oncology) has long served as one of the most widely utilized first-line anti-VEGF therapies in retina care. However, because no FDA-approved ophthalmic formulation existed, retina specialists had to rely on compounding pharmacies to aliquot and repackage intravenous oncology vials into tiny syringes for intravitreal injection. This off-label process raised serious concerns regarding:
- Sterility and Safety: Compounding errors have historically led to severe intraocular infections (endophthalmitis) and blindness.
- Product Quality and Dosage Consistency: Repackaged formulations lacked standardized quality controls and FDA-approved labeling.
Lytenava fundamentally alters this clinical landscape by providing a dedicated, purpose-built formulation manufactured specifically for the eye under strict FDA regulatory oversight and validated quality systems.
Regulatory Path and Commercial Launch
The approval follows a protracted regulatory path, which included multiple complete response letters (CRLs) before Outlook successfully appealed and resubmitted its biologics license application (BLA) in June 2026. The FDA's Office of New Drugs (OND) ultimately concluded that Outlook established "substantial evidence of effectiveness" under the NORSE clinical program.
- Exclusivity: Outlook Therapeutics anticipates receiving 12 years of reference product exclusivity under the Biologics Price Competition and Innovation Act (BPCIA).
- Commercial Availability: Outlook expects to make Lytenava commercially available to eligible patients in the United States before the end of 2026, backed by comprehensive patient assistance and reimbursement programs.
- Global Footprint: Lytenava (marketed as bevacizumab gamma in Europe) already holds marketing authorizations from the European Commission and the UK's MHRA, with commercial launches underway in Germany, Austria, and the United Kingdom.
"For more than two decades, bevacizumab has served as one of the most widely utilized anti-VEGF therapies in retina care despite the absence of an FDA-approved ophthalmic formulation. LYTENAVA™ fundamentally changes that landscape. Rather than relying on repackaged formulations originally intended for intravenous use, physicians now have access to a purpose-built ophthalmic formulation of bevacizumab designed specifically for intravitreal administration that delivers the manufacturing consistency, product quality, and regulatory oversight patients deserve." — Bob Jahr, CEO of Outlook Therapeutics